Results from OVATION 2 Study of IMNN-001 to be highlighted in late-breaking acceptanceCompany also announces FDA End-of-Phase 2 in-person meeting ...
News Medical on MSN9d
Phase 3 trial assesses clazakizumab in kidney transplant recipients with caAMRChronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the ...
Compass Pathways' latest update reveals extended trial timelines, staff cuts, and financial concerns, raising questions about ...
Ventus Therapeutics announced the successful completion of the phase 1 clinical trial for VENT-03 with plans to initiate a ...
However, a phase 2 trial in the setting ran into challenges ... Editor's note: This story was updated at 10 am on Oct. 3 to include comments from Takeda.
MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 ...
GlycoMimetics (GLYC) announced the Phase 2 analysis of the adaptive Phase 2/3 study of uproleselan being conducted by the National Cancer ...
According to the company, Duravyu 2.7mg demonstrated an early and sustained anatomical improvement mirroring BCVA results with a 68 micron reduction in CST. Full topline data is anticipated in Q1 of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback